78 related articles for article (PubMed ID: 10557063)
1. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
[TBL] [Abstract][Full Text] [Related]
2. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
Kumar A; Ehrenshaft M; Tokar EJ; Mason RP; Sinha BK
Biochim Biophys Acta; 2016 Jul; 1860(7):1519-27. PubMed ID: 27095671
[TBL] [Abstract][Full Text] [Related]
3. Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors.
Peleg R; Romzova M; Kogan-Zviagin I; Apte RN; Priel E
BMC Cancer; 2014 Dec; 14():910. PubMed ID: 25472619
[TBL] [Abstract][Full Text] [Related]
4. Multi-target rational design and synthesis of novel diphenyl-tethered pyrazolopyrimidines targeting EGFR and topoisomerase II with potential DNA intercalation and apoptosis induction.
Gaber AA; Abo Elmaaty A; Sharaky M; Mosa AA; Yahya Abdullah Alzahrani A; Shaaban S; Eldehna WM; Al-Karmalawy AA
Bioorg Chem; 2024 Apr; 145():107223. PubMed ID: 38387399
[TBL] [Abstract][Full Text] [Related]
5. Chromatin damage generated by DNA intercalators leads to degradation of RNA Polymerase II.
Espinoza JA; Kanellis DC; Saproo S; Leal K; Martinez JF; Bartek J; Lindström MS
Nucleic Acids Res; 2024 May; 52(8):4151-4166. PubMed ID: 38340348
[TBL] [Abstract][Full Text] [Related]
6. Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells.
Kikuchi Y; Hirata J; Yamamoto K; Ishii K; Kita T; Kudoh K; Tode T; Nagata I; Taniguchi K; Kuwano M
Jpn J Cancer Res; 1997 Feb; 88(2):213-7. PubMed ID: 9119751
[TBL] [Abstract][Full Text] [Related]
7. Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity.
Menendez D; Anand JR; Murphy CC; Bell WJ; Fu J; Slepushkina N; Buehler E; Martin SE; Lal-Nag M; Nitiss JL; Resnick MA
Oncotarget; 2022; 13():332-346. PubMed ID: 35178190
[TBL] [Abstract][Full Text] [Related]
8. Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage.
Keresteš V; Kubeš J; Applová L; Kollárová P; Lenčová-Popelová O; Melnikova I; Karabanovich G; Khazeem MM; Bavlovič-Piskáčková H; Štěrbová-Kovaříková P; Austin CA; Roh J; Štěrba M; Šimůnek T; Jirkovská A
Toxicol Sci; 2024 Mar; 198(2):288-302. PubMed ID: 38290791
[TBL] [Abstract][Full Text] [Related]
9. A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.
Bisacchi GS; Hale MR
Curr Med Chem; 2016; 23(6):520-77. PubMed ID: 26695512
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage.
Barker CR; McNamara AV; Rackstraw SA; Nelson DE; White MR; Watson AJ; Jenkins JR
Nucleic Acids Res; 2006; 34(4):1148-57. PubMed ID: 16504968
[TBL] [Abstract][Full Text] [Related]
11. Cell cycle responses to Topoisomerase II inhibition: Molecular mechanisms and clinical implications.
Soliman TN; Keifenheim D; Parker PJ; Clarke DJ
J Cell Biol; 2023 Dec; 222(12):. PubMed ID: 37955972
[TBL] [Abstract][Full Text] [Related]
12. Paraoxon and glyphosate induce DNA double-strand breaks but are not type II topoisomerase poisons.
Montero-Montoya R; Suárez-Larios K; Serrano-García L
Mutat Res Genet Toxicol Environ Mutagen; 2023; 890():503657. PubMed ID: 37567644
[TBL] [Abstract][Full Text] [Related]
13. Loss of drug-stimulated topoisomerase II DNA breaks in living cells is different at two unrelated loci.
Binaschi M; Borgnetto ME; Capranico G
Nucleic Acids Res; 2000 Sep; 28(17):3289-93. PubMed ID: 10954596
[TBL] [Abstract][Full Text] [Related]
14. Naturally mutagenic sequence diversity in a human type II topoisomerase.
Bandak AF; Blower TR; Nitiss KC; Gupta R; Lau AY; Guha R; Nitiss JL; Berger JM
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302064120. PubMed ID: 37406101
[TBL] [Abstract][Full Text] [Related]
15. Narciclasine, a novel topoisomerase I inhibitor, exhibited potent anti-cancer activity against cancer cells.
Wang M; Liang L; Wang R; Jia S; Xu C; Wang Y; Luo M; Lin Q; Yang M; Zhou H; Liu D; Qing C
Nat Prod Bioprospect; 2023 Aug; 13(1):27. PubMed ID: 37640882
[TBL] [Abstract][Full Text] [Related]
16. Hellebrigenin triggers death of promyelocytic leukemia cells by non-genotoxic ways.
Cavalcanti BC; Soares BM; Barreto FS; Magalhães HIF; Ferreira JRO; Almeida ATA; Araújo Beserra Filho JI; Silva J; Dos Santos HS; Marinho ES; Furtado CLM; Moraes Filho MO; Pessoa C; Ferreira PMP
Toxicon; 2024 Feb; 238():107591. PubMed ID: 38160738
[TBL] [Abstract][Full Text] [Related]
17. DNA-AP sites generation by etoposide in whole blood cells.
Rojas E; Mussali P; Tovar E; Valverde M
BMC Cancer; 2009 Nov; 9():398. PubMed ID: 19917085
[TBL] [Abstract][Full Text] [Related]
18. Two CD95 tumor classes with different sensitivities to antitumor drugs.
Algeciras-Schimnich A; Pietras EM; Barnhart BC; Legembre P; Vijayan S; Holbeck SL; Peter ME
Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11445-50. PubMed ID: 14504390
[TBL] [Abstract][Full Text] [Related]
19. Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents.
Yakkala PA; Penumallu NR; Shafi S; Kamal A
Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895927
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of luotonin A-derived topoisomerase targeting scaffold with potent antitumor effect and low genotoxicity.
Li XW; Fang SJ; Li YZ; Qin LQ; Chen NY; Zheng B; Mo DL; Su GF; Su JC; Pan CX
Bioorg Chem; 2024 Feb; 143():107015. PubMed ID: 38086241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
